Table 2.
Demographics of included participants
| Controls | SZ | SZA | BP | Relatives | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | 243 | 157 | 90 | 141 | 300 | ||||||||||
| Mean age (sd)a | 37.5 (12.3) | 34.3 (12.2) | 35.7 (12.2) | 36.6 (13.0) | 39.8 (16.1) | ||||||||||
| Race Distributionb,c | AA | CA | OT | AA | CA | OT | AA | CA | OT | AA | CA | OT | AA | CA | OT |
| 66 | 155 | 22 | 67 | 77 | 13 | 38 | 46 | 6 | 32 | 102 | 7 | 86 | 199 | 15 | |
| 27% | 64% | 9% | 43% | 49% | 8% | 42% | 51% | 7% | 23% | 72% | 5% | 29% | 66% | 5% | |
| Gender Distributionb | F | M | F | M | F | M | F | M | F | M | |||||
| 129 | 114 | 56 | 101 | 50 | 40 | 97 | 44 | 212 | 88 | ||||||
| 53% | 47% | 36% | 64% | 56% | 44% | 69% | 31% | 71% | 29% | ||||||
| Mean Family Hollingshead Score (sd)a | 39 (15) | 42 (16) | 46 (17) | 38 (16) | 42 (16) | ||||||||||
| Mean total PANSS score (sd)a | NA | 66 (17) | 69 (16) | 54 (14) | NA | ||||||||||
| Mean Intracranial Volume (sd)a | 1450 cc (198) | 1486 cc (198) | 1389 cc (186) | 1435 cc (169) | 1435 cc (178) | ||||||||||
| Mean Current Choloropromazine Equivalent Dosage (sd)a | 0 mg/day (0) | 349 mg/day (406) | 378 mg/day (491) | 236 mg/day (456) | 3 mg/day (28) | ||||||||||
| Current Lithium Usage Distributionb,d | Li | No Li | Li | No Li | Li | No Li | Li | No Li | Li | No Li | |||||
| 0 | 243 | 42 | 99 | 8 | 82 | 13 | 144 | 3 | 297 | ||||||
| 0% | 100% | 30% | 70% | 9% | 81% | 8% | 92% | 1% | 99% | ||||||
a
Significantly different between groups by one way ANOVA
b
Significantly different between groups by chi-squared test
c
AA – African American; CA – Caucasian; OT – Other
d
Li – Presently using lithium; No Li – Not presently using lithium